期刊文献+

调控A20对NF-κB表达及Jurkat细胞的影响 被引量:3

Effect of Regulating A20 Expression on NF-κB Expression and Biological Characteristics of Jurkat Cells
下载PDF
导出
摘要 目的:探讨在急性T淋巴细胞白血病糖皮质激素耐药Jurkat细胞株中,调控A20对NF-κB表达以及Jurkat细胞生物学特性的影响。方法:CCRF CEM和Jurkat细胞中分别加入100、10、1、0.1、0.01和0.001μmol/L地塞米松(DEX),培养24、48和72 h,应用CCK-8检测细胞增殖抑制的变化。构建A20质粒,设计并合成A20-siRNA,分别通过脂质体转染Jurkat细胞,CCK-8检测不同浓度DEX处理组、不同浓度DEX联合A20质粒和A20-siRNA处理组的Jurkat细胞增殖率。应用RT-qPCR检测NF-κB的m RNA表达水平,Western bolt检测蛋白表达水平,采用流式细胞术检测Jurkat细胞凋亡。结果:不同浓度地塞米松(DEX)对CCRF CEM细胞生长的抑制作用呈显著的时间依赖性(r=0.984,P<0.05)和浓度依赖性(r=0.966,P<0.05);CCRF CEM细胞在24 h时,IC50接近1μmol/L,Jurkat细胞在1μmol/L和10μmol/L开始出现较大差异。由于1μmol/L DEX处理的Jurkat细胞增殖率无明显变化,故选取1μmol/L DEX处理的Jurkat细胞为对照组。检测显示A20质粒转染联合不同浓度DEX处理组细胞增殖率较DEX组及A20-siRNA联合DEX组低(P<0.05)。A20质粒转染Jurkat细胞后,NF-κB的mRNA及蛋白表达明显低于对照组(P<0.05),细胞凋亡率较对照组明显增高(P<0.05);A20-siRNA转染Jurkat细胞后,NF-κB的mRNA及蛋白表达水平明显高于对照组(P<0.05),A20-siRNA组细胞的凋亡率与对照组无明显改变(P>0.05)。结论:Jurkat细胞对DEX耐药,A20过表达联合DEX可增加对DEX耐药细胞的敏感性,降低Jurkat细胞增殖率;下调Jurkat细胞中NF-κB的表达水平,促进Jurkat细胞的凋亡。 Objective:To explore the effect of regulating A20 expression on NF-κB and biological characteristics of Jurkat cells with glucocorticoid(GC)resistance.Methods:CCRF CEM and Jurkat cells were treated with dexamethasone(DEX)at concentrations of 100、10、1、0.1、0.01 and 0.001μmol/L,and cultured for 24、48 and 72 h.The proliferation inhibition rate of Jurkat cell was detected by CCK-8.A20 plasmid was constructed,A20-siRNA was designed and synthesized,and transfected into Jurkat cells by liposome.CCK-8 was used to detect the proliferation rates of Jurkat cells in different concentrations of DEX group,DEX combined with A20 plasmid group and A20-siRNA group.The mRNA expression level of NF-κB was detected by RT-qPCR,the protein expression level of NF-κB was detected by Western blot,and the apoptosis of Jurkat cells was examined by flow cytometry.Results:The inhibitory effects of DEX at different concentrations on the growth of CCRF CEM cells were time-dependent(r=0.984,P<0.05)and concentration-dependent(r=0.966,P<0.05).At the point of 24 hour,the IC50 approached 1μmol/L in CCRF CEM cells.Great large differences began to appear between 1 and 10μmol/L,the proliferation rate of Jurkat cells treated with 1μmol/L DEX did not show a significant change.Therefore,1μmol/L was selected as control group.The cell proliferation rate of A20 plasmid transfection combined with different concentrations of DEX group was lower than that of DEX group and A20-siRNA combined with DEX group.After transfection of A20 plasmid,the expression level of NF-κB was significantly lower than that of control group(P<0.05),and the apoptotic rate was significantly higher than that of control group(P<0.05).After transfection of Jurkat cells with A20-siRNA,the expression level of NF-κB was significantly higher than that of control group(P<0.05).The apoptotic rate of cells in A20-siRNA group was not significantly changed(P>0.05).Conclusion:Jurkat cells are resistant to DEX.A20 overexpression combined with DEX can increase sensitivity of Jurkat cells with GC resistance and decrease the proliferation rate of Jurkat cells,down-regulate the expression level of NF-κB and promote the apoptosis of Jurkat cells.
作者 王哲 肖仕珊 丁倩 王清 周胜楠 李哲 朱红倩 WANG Zhe;XIAO Shi-Shan;DING Qian;WANG Qing;ZHOU Sheng-Nan;LI Zhe;ZHU Hong-Qian(Department of Hematology,Guizhou Provincial People′s Hospital,Guiyang 550002,Guizhou Province,China)
出处 《中国实验血液学杂志》 CAS CSCD 北大核心 2020年第4期1144-1151,共8页 Journal of Experimental Hematology
基金 贵州省高层次人才科研条件特助经费项目(TZJF-2010-099)。
关键词 A20 NF-ΚB T淋巴细胞白血病 耐药 RNA干扰 A20 NF-κB T-cell acute lymphoblastic leukemia durg-resistance RNA interference
  • 相关文献

参考文献4

二级参考文献69

  • 1帖利军,顾龙君,宋得莲,蒋黎敏,薛惠良,汤静燕,董璐,潘慈,陈静,叶辉.儿童急性淋巴细胞白血病早期治疗反应的预后价值:上海儿童医学中心单中心的临床报告(英文)[J].中国当代儿科杂志,2009,11(1):5-9. 被引量:3
  • 2沈松杰,郭俊超,廖泉,赵玉沛.MAPK信号转导通路在肿瘤化疗耐药中的作用[J].国外医学(肿瘤学分册),2005,32(8):579-582. 被引量:9
  • 3何莉,刘云鹏,侯科佐,朱志图,李丹,张敬东.地塞米松诱导CEM细胞凋亡过程中Survivin和Caspase-3基因表达的研究[J].中华肿瘤防治杂志,2006,13(19):1464-1467. 被引量:5
  • 4Moricke A, Reiter A, Zimmermann M, et al. Risk - adjusted therapy of acute lymphoblastie leukemia can decrease treatment burden and improve survival:Treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL - BFM 95 [ J ]. Blood, 2008,111 ( 9 ) : 4477 - 4489.
  • 5Carter BZ, Mak DH, Schober WD, et al. Regulation of survivin expression through Bcr - Abl/MAPK cascade: Targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib -responsive CML ceils [ J ]. Blood,2006,107 (4) : 1555 - 1563.
  • 6Fulda S. Therapeutic opportunities for counteracting apoptosis resistance in childhood leukaemia[J].Br J Haematol,2009,145 (4) :441 - 454.
  • 7Yamamoto H, Ngan CY, Monden M. Cancer cells survive with survivin [ J]. Cancer Sci,2008,999 (9) : 1709 - 1714.
  • 8Altieri DC. Survivin, cancer networks and pathway - directed drug discovery[ J]. Nat Rev Cancer,2008,8 ( 1 ) :61 - 70.
  • 9Ling X, Calinski D, Chanan - Khan AA, et al. Cancer cell sensitivity to bortezomib is associated with survivin expression and p53 status but not cancer cell types[ J]. J Exp Clin Cancer Res ,2010,29 ( 1 ) : 1 - 10.
  • 10Fukuda S, Foster RG, Porter SB, et al. The antiapoptosis protein survivin is associated with cell cycle entry of normal cord blood CD34 + cells and modulates cell cycle and proliferation of mouse hematopoietic progenitor cells [ J ]. Blood,2002,100 (7) :2463 - 2471.

共引文献11

同被引文献25

引证文献3

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部